Eventide Asset Management’s Aura Biosciences AURA Stock Holding History

Eventide Asset Management’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,080,605	Closed	-$33.5M	–	221
2024 Q4	$33.5M	Sell	4,080,605 -1,722,077	-30%	-$16.2M	0.61%	51
2024 Q3	$51.7M	Hold	5,802,682	–	–	0.89%	40
2024 Q2	$43.9M	Hold	5,802,682	–	–	0.75%	45
2024 Q1	$45.6M	Hold	5,802,682	–	–	0.71%	51
2023 Q4	$51.4M	Buy	5,802,682 +2,777,777	+92%	+$23.5M	0.84%	43
2023 Q3	$27.1M	Buy	3,024,905 +89,386	+3%	+$962K	0.49%	60
2023 Q2	$36.3M	Buy	2,935,519 +409,689	+16%	+$4.38M	0.61%	51
2023 Q1	$23.4M	Buy	2,525,830 +274,462	+12%	+$2.85M	0.43%	72
2022 Q4	$23.6M	Buy	+2,251,368	New	+$28.7M	0.47%	70

Other funds holding AURA

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Eventide Asset Management's AURA Position: Q1 2025 in Review

Eventide Asset Management sold out of Aura Biosciences (AURA) in Q1 2025, closing a stake of 4,080,605 shares — an estimated $33.5M sold.

Eventide Asset Management first reported a position in AURA in Q4 2022 and held it in 9 quarters. The position peaked at $51.7M in Q3 2024. 94 funds tracked by Wall St. Rank hold AURA as of Q1 2025.

Eventide Asset Management reported no remaining Aura Biosciences position as of Q1 2025 after selling out during the quarter.
Eventide Asset Management sold 4,080,605 Aura Biosciences shares in Q1 2025, an estimated $33.5M.
Eventide Asset Management first reported a position in Aura Biosciences in Q4 2022 and held it in 9 quarters.
Eventide Asset Management's Aura Biosciences position peaked at $51.7M in Q3 2024.
94 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2025.

Based on Eventide Asset Management's 13F filing for Q1 2025, filed 15 May 2025.